Editas Medicine (EDIT) Net Cash Flow (2015 - 2025)

Editas Medicine (EDIT) has 11 years of Net Cash Flow data on file, last reported at $25.9 million in Q3 2025.

• Quarterly Net Cash Flow fell 17.5% year-over-year to $25.9 million in Q3 2025, while the trailing twelve-month figure through Dec 2025 was $32.9 million (up 317.04% YoY) and the FY2024 annual result came in at $7.9 million, up 144.15% from the prior year.
• Net Cash Flow advanced to $25.9 million in Q3 2025 per EDIT's latest filing, from -$150000.0 in the prior quarter.
• Across five years, Net Cash Flow topped out at $215.2 million in Q1 2021 and bottomed at -$138.3 million in Q3 2023.
• The 5-year median for Net Cash Flow is -$150000.0 (2025), against an average of $1.3 million.
• The widest annual swing landed in 2021, when Net Cash Flow jumped 4804.61%; it then slumped 434.79% in 2023.
• Tracing EDIT's Net Cash Flow over 5 years: stood at -$56.4 million in 2021, then decreased by 22.74% to -$69.2 million in 2022, then surged by 159.43% to $41.1 million in 2023, then fell by 13.15% to $35.7 million in 2024, then slipped by 27.47% to $25.9 million in 2025.
• Per Business Quant, the three latest EDIT Net Cash Flow figures stand at $25.9 million (Q3 2025), -$150000.0 (Q2 2025), and $7.2 million (Q1 2025).

Peer Comparison